{
  "slug": "personalis-next-personal",
  "name": "Personalis (NeXT Personal)",
  "description": "Personalis is a cancer genomics company that provides advanced genomic sequencing and analytics for precision medicine. Its flagship NeXT Platform, particularly NeXT Personal, is designed to detect minimal residual disease (MRD) with ultra-high sensitivity by identifying a personalized signature of up to 1,800 mutations in a patient's tumor.",
  "url": "https://optimly.ai/brand/personalis-next-personal",
  "logoUrl": "",
  "baiScore": 72,
  "archetype": "Challenger",
  "category": "Biotechnology",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [
    {
      "slug": "adaptive-biotechnologies",
      "name": "Adaptive Biotechnologies"
    },
    {
      "slug": "foundation-medicine",
      "name": "Foundation Medicine"
    },
    {
      "slug": "natera-signatera",
      "name": "Natera (Signatera)"
    }
  ],
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-04-10T06:13:57.367+00:00",
  "verifiedVitals": {
    "website": "personalis.com",
    "founded": "2011",
    "headquarters": "Menlo Park, California",
    "pricing_model": "Enterprise/Custom (Clinical Reimbursement)",
    "core_products": "NeXT Personal, ImmunoID NeXT, NeXT DX",
    "key_differentiator": "NeXT Personal uses a whole-genome-informed approach to track up to 1,800 mutations, offering significantly higher sensitivity than standard exome-based MRD tests.",
    "target_markets": "Oncologists, Biopharmaceutical Companies, Clinical Researchers",
    "employee_count": "200-500",
    "funding_stage": "Public (Nasdaq: PSNL)",
    "subcategory": "Precision Oncology / Molecular Diagnostics"
  },
  "intentTags": {
    "problemIntents": [
      "Standard Pathology Monitoring: Hospital pathology departments manually performing tissue staining and analysis without personalized longitudinal monitoring.",
      "Clinical Research Agencies: Hiring specialized clinical research organizations to manage patient monitoring data manually."
    ],
    "solutionIntents": [
      "ultra-sensitive MRD testing oncology",
      "tumor-informed liquid biopsy companies",
      "whole genome cancer recurrence monitoring",
      "NeXT personal clinical trial results",
      "best test for early cancer recurrence detection",
      "Adjacent Screening Tools: Utilizing liquid biopsy tools designed for early detection (e.g., GRAIL) rather than post-diagnosis recurrence monitoring."
    ],
    "evaluationIntents": []
  },
  "timestamp": 1777944399905
}